Life science news 24 August 2026: the FDA clears Regeneron’s Pasatru for an ultra-rare bone disorder and grants Ultragenyx the first gene therapy for glycogen storage disease type Ia, authorises the first standalone robotic blood-draw device, and the MHRA opens a licensing route for microbiome-based medicines in a rare disease and regulatory-heavy week for pharma, biotech and healthcare.
The US Food and Drug Administration approved Pasatru (garetosmab-grts, Regeneron) on 19 August to reduce the formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva, an ultra-rare condition in which soft tissue is progressively replaced by bone. The FDA describes it as the second drug approved for the disease, after Ipsen’s Sohonos (palovarotene) in 2023, while Regeneron positions it as the first shown in a placebo-controlled trial to cut both new lesions and flare-ups. Approval rests on the Phase 3 OPTIMA trial (NCT05394116), a randomised, double-blind study of 63 adults given garetosmab 3mg/kg, garetosmab 10mg/kg or placebo intravenously every four weeks for 56 weeks, after which participants could elect a double-blind extension of at least 84 weeks or an observation-only arm.
The primary endpoint counted new lesions at week 56 using full-body low-dose computed tomography. The agency reported two new lesions among 23 patients on 10mg/kg and one among 19 on 3mg/kg, against 19 among 21 on placebo, a reduction Regeneron characterises as 90 per cent or greater. Clinician-assessed flare-ups numbered nine, 53 and 66 respectively, a clear separation at the higher dose but a much narrower one at 3mg/kg, and patient-reported rates did not differ significantly from placebo. The starting dose is 10mg/kg over 60 minutes every four weeks, reducible to 3mg/kg if not tolerated, and it can be given in settings including home infusion. The label warns of fetal harm in pregnancy, skin and soft tissue infections, and nosebleeds. Pasatru holds Breakthrough Therapy, Fast Track, Orphan Drug and Priority Review designations, and while Regeneron has not confirmed a list price, trade reporting puts the annual cost at $693,000 to $2.1 million.
Ultragenyx announced on 19 August that the FDA has granted accelerated approval to Genglycos (pariglasgene brecaparvovec-opnr), previously DTX401, for adult and paediatric patients aged eight and older with glycogen storage disease type Ia. The one-time adeno-associated virus gene therapy is the first approved treatment designed to address the underlying cause of the disorder, although the approved indication is narrower than that framing suggests: it is cleared to reduce daily cornstarch intake as an adjunct to nutritional management. A deficiency of glucose-6-phosphatase leaves the liver unable to release glucose into the bloodstream, exposing patients to life-threatening hypoglycaemia and requiring a round-the-clock regimen of raw cornstarch. Ultragenyx puts prevalence at 1,500 to 2,500 patients in the United States and 6,000 to 8,000 worldwide within commercially accessible geographies.
Approval is based on the 48-week randomised, double-blind, placebo-controlled Phase 3 GlucoGene study, which treated 46 participants aged eight and above and showed a statistically significant reduction in cornstarch requirement, with 44 in the modified intention-to-treat population. Continued approval may depend on verification of clinical benefit, and Ultragenyx will supply two years of data from commercial treatment of 50 patients alongside 20 controls who cannot receive the therapy because of anti-AAV8 antibodies. Genglycos is contraindicated in severe hepatic fibrosis or cirrhosis and warns of hypersensitivity and infusion reactions including anaphylaxis, immune-mediated hepatotoxicity and adrenal insufficiency. Eric Crombez, Chief Medical Officer at Ultragenyx, said in the company announcement that the therapy would establish the normal breakdown of glycogen during fasting or metabolic stress. It is the company’s first gene therapy approval and fifth FDA approval overall, and came with a priority review voucher.
BioMarin Pharmaceutical announced on 18 August that it has agreed to acquire Netherlands-based Alesta Therapeutics for $275 million upfront plus up to $215 million in development and regulatory milestones. The deal is structured around a single asset, ALE1, an orally active small molecule for hypophosphatasia, a rare genetic bone disease caused by ALPL mutations that impairs bone and tooth mineralisation and can cause frequent fractures, early tooth loss and, in adults, muscle weakness, fatigue and pain. ALE1 inhibits a target that regulates inorganic pyrophosphate, the metabolite at the centre of the disease, and BioMarin frames it as a potential first oral alternative to the injectable therapies available today. The only approved enzyme replacement therapy is AstraZeneca and Alexion’s Strensiq (asfotase alfa), given by subcutaneous injection.
ALE1 is in a Phase 1/2a trial assessing safety, tolerability and pharmacokinetics in healthy volunteers and adults with the condition, and will sit within BioMarin’s Skeletal Conditions Business Unit after completion. More than 9,000 people have been diagnosed with hypophosphatasia in the United States, although BioMarin says it is often underdiagnosed. Immediately before completion, Alesta will spin out all non-ALE1 assets to a new entity and transfer its employees there, so no Alesta staff will join BioMarin. Alexander Hardy, chief executive of BioMarin, said the candidate could reach the company’s largest addressable patient population, while Alesta Chief Executive Ilan Ganot cited BioMarin’s rare disease commitment. The transaction will be funded from cash on hand, is expected to close this quarter and to be modestly dilutive to 2026 results excluding the upfront.
LEO Pharma said on 18 August that it has agreed to acquire worldwide rights to dersimelagon from Japan’s Tanabe Pharma, in a transaction worth up to $435 million in upfront and near-term milestone payments, with further downstream milestones and tiered royalties on net sales payable if the medicine is approved. Dersimelagon is an oral, once-daily melanocortin 1 receptor agonist that increases melanin production in the skin to reduce light penetration, and it is being developed for erythropoietic protoporphyria and X-linked protoporphyria, two rare inherited disorders that cause severe sunlight-induced skin pain and, in some patients, liver damage. The only approved therapy for erythropoietic protoporphyria is afamelanotide (Scenesse), a subcutaneous implant licensed for adults, and LEO says that if dersimelagon is cleared it would be the first oral treatment for the two conditions.
A new drug application covering both indications was submitted to the FDA in June 2026, supported by the global, randomised, double-blind, placebo-controlled Phase 3 INSPIRE study. LEO says the trial met its primary and secondary endpoints, including a significant prolongation of average daily sunlight exposure time to first prodromal symptoms. Tanabe, which reported topline results in January and fuller data on 30 March, randomised 165 adults and adolescents to dersimelagon 200mg or placebo once daily over 16 weeks, followed by a 36-week open-label extension. Christophe Bourdon, Chief Executive of LEO Pharma, said the asset addresses a clear unmet need, while Tanabe Chief Executive Akihisa Harada pointed to LEO’s dermatology expertise and global reach. The asset carries Fast Track and Orphan Drug designations, and the deal follows the Danish group’s acquisition of Replay and its Spevigo partnership with Boehringer Ingelheim, with an updated 2026 outlook issued alongside its half-year interim report the same day.
In further life science news 24 August 2026, the week also brought a first-of-its-kind device authorisation, a formal FDA consultation on regulating generative artificial intelligence in medical devices, a nomination for FDA commissioner, two UK developments covering microbiome medicines and diabetes prescribing costs, and a reverse merger that redirects a struggling biotech into migraine.
The FDA authorised the Aletta on 19 August, the first standalone robotic device cleared in the United States to draw blood from a patient’s arm without hands-on operator intervention. Developed by Netherlands-based Vitestro and cleared through the De Novo pathway for low to moderate risk devices of a new type, it is authorised for adults in outpatient settings under supervision by someone trained in phlebotomy, with one phlebotomist permitted to oversee three devices at once. It uses near-infrared light and Doppler ultrasound to locate a suitable vein and distinguish it from an artery, declining to proceed if none is found, then applies the tourniquet, prepares the skin, inserts and disposes of the needle, changes tubes and applies a bandage, detaching the needle automatically if the patient moves excessively.
Clinical testing reviewed by the agency found blood-draw success rates comparable to or better than trained phlebotomists where the device proceeded, across patients of varying health status and skin tone and those self-reporting difficult vein access, with device-related adverse events uncommon and mild. Michelle Tarver, Director of the FDA’s Center for Devices and Radiological Health, framed the decision against a growing shortage of trained phlebotomists, and the agency set special controls covering labelling, performance and clinical testing that comparable devices must meet. The authorisation opens the US market to a device already established in Europe: Vitestro secured a CE mark in 2024 and has since sold the Aletta on a limited basis there, according to trade reporting.
The FDA also issued a discussion paper on 18 August setting out preliminary considerations for regulating generative artificial intelligence-enabled medical devices, and opened a public docket seeking views on risk assessment, premarket evaluation and postmarket monitoring. The paper, led by the Digital Health Center of Excellence within the Center for Devices and Radiological Health, proposes a premarket approach built on competency assessment, loosely modelled on how physicians are trained and evaluated, combining non-clinical benchmarking with clinical confirmation before a system reaches patients.
It also describes risk-proportionate postmarket monitoring, acknowledging that generative systems may behave differently over time than static software, and addresses two areas it flags as technically complex: foundation models underpinning multiple downstream applications, and agentic systems capable of autonomous decision-making with limited oversight. The agency stresses that the paper proposes no policy change and does not address whether the approaches described sit within its existing legal authority. Acting FDA Commissioner Kyle Diamantas said the United States must lead in shaping how the technology is developed and used safely, while DHCoE Director Rick Abramson said the agency has a responsibility to provide leadership. Comments close under docket FDA-2026-N-7874 on Regulations.gov on 19 October 2026.
The question of who will run the agency also moved on. President Donald Trump announced on 19 August that he would nominate Heidi Overton, Deputy Director of the White House Domestic Policy Council, as FDA commissioner. Overton is a physician who completed a general surgery residency at Johns Hopkins and served as a White House fellow during the first Trump term. The post has been held on an acting basis by Kyle Diamantas since Marty Makary resigned in May, and officials have said Diamantas turned down the permanent role more than once for personal reasons. The nomination requires Senate confirmation, and Bill Cassidy, who chairs the Senate Health, Education, Labor and Pensions Committee, has said he holds strong concerns about her lack of experience running a large organisation.
The Medicines and Healthcare products Regulatory Agency published a position paper on 18 August clarifying how microbiome-based medicinal products can be licensed in the UK, intended to encourage developers to pursue British routes to market. Such products, which work by modulating, restoring or replacing components of the human microbiome, already fall within the existing framework set out in the Human Medicines Regulations 2012, so no separate pathway is required, and depending on their characteristics they may be regulated as biological medicinal products or, in some cases, as advanced therapy medicinal products.
The paper sets out the ground developers should cover, including product characterisation, manufacturing consistency, control of batch-to-batch variability, safety assessment encompassing antimicrobial resistance risk, and robust clinical evidence. It also clarifies arrangements for faecal microbiota transplantation, used in the UK chiefly for recurrent Clostridioides difficile infection and supplied through clinical trials or as an unlicensed medicine, routes that remain the prescribing clinician’s responsibility and are unaffected. No microbiome-based medicinal product holds a UK marketing authorisation, a position the MHRA contrasts with the United States, where two donor-derived microbiota products are licensed for C. difficile. Julian Beach, MHRA executive director of healthcare quality and access, described the field as one of the most interesting and fast-moving areas in medicine today and said early engagement is the most effective route to navigate it. The MHRA also flags the EU Substances of Human Origin Regulation, which will introduce a separate framework for intestinal microbiota interventions across the bloc.
The NHS Business Services Authority published its annual diabetes prescribing statistics on 20 August, showing that the cost of items prescribed to treat diabetes in England more than doubled to £2.31 billion over the decade to 2025/26 and now accounts for 20 per cent of total spending on all prescribed items, up from 11 per cent in 2016/17. There were 83 million items prescribed, up 60 per cent on the 52 million recorded in 2016/17 and 8 per cent on the previous year, dispensed to an estimated 4.1 million identified patients, itself up 46 per cent over the decade.
Anti-diabetic drugs were the most prescribed treatment, making up 77 per cent of items and 64 per cent of the total cost, with 64 million items dispensed at a cost of £1.5 billion. The authority attributes much of the increase to SGLT2 inhibitors including dapagliflozin and empagliflozin, GLP-1 receptor agonists including tirzepatide and semaglutide, and improved glucose monitoring using interstitial fluid sensors. Men aged 65 to 69 were the most commonly treated group, at an estimated 300,000 patients or 7 per cent of the total, and an estimated 386,000 more patients received diabetes items in the most deprived areas than the least deprived, a gradient persisting across successive editions.
Fulcrum Therapeutics and Slate Medicines announced on 17 August that they have agreed to combine in an all-stock transaction, with the resulting company to operate as Slate Medicines and trade on Nasdaq as SLTE. The structure is a reverse merger: pre-merger Fulcrum stockholders are expected to hold 5.0 per cent of the combined company and Slate holders, including financing participants, 95.0 per cent, subject to adjustment for Fulcrum’s net cash at closing. Fulcrum is expected to contribute about $20.3 million in net cash and pay an estimated $270.0 million dividend to its stockholders immediately before completion.
Slate has secured an oversubscribed private placement of $245 million led by Frazier Life Sciences, expected to fund operations into 2029 while advancing SLTE-1009, a subcutaneous anti-PACAP and VIP monoclonal antibody for migraine prevention. The antibody has been cleared to begin a Phase 1 healthy volunteer study in Australia, with initial data expected in mid-2027, ahead of a Phase 2 dose-ranging study. The combined company will be led by Slate chief executive Gregory Oakes with a five-member board designated by Slate. Fulcrum discontinued its sickle cell candidate pociredir on 1 June and began a strategic review after FDA feedback on secondary haematologic malignancies seen with the PRC2 inhibitor Tazverik, withdrawn globally in March, left no viable regulatory path. Chief Executive Alex Sapir called the merger a route for shareholders into a next-generation migraine portfolio. Closing is targeted for the fourth quarter of 2026, subject to shareholder and antitrust approvals and Nasdaq listing.
That’s your life science news digest for 24 August 2026, back next Monday with the latest from pharma, biotech and healthcare at www.lifesciencedaily.news. Catch up on the 17 August news roundup
